Azenta(NASDAQ) AZTA

Azenta helps scientists manage and study biological samples used in medical research. It provides automated systems that store these samples at very cold temperatures to keep them safe. These tools help drug companies and labs develop new medicines faster.

What Azenta Provides

• Sample Management Solutions: Automated storage systems for biological samples and chemical compounds; includes ultra-cold freezers and sample handling equipment.
• Multiomics Services: Laboratory services for analyzing genes and DNA; includes genomic sequencing and gene synthesis to support drug discovery.
• Sample Repository Services: Off-site storage and management programs for research samples; allows labs to outsource their specimen collections.
• Consumables and Instruments: Specialized tubes, caps, and scanners used to track samples throughout the research process.

Recent Strategic Moves

• Announced the plan to sell the B Medical Systems business in November 2024 to focus on core life sciences operations.
• Entered into a definitive agreement with Thelema S.À R.L. in December 2025 to sell the B Medical Systems unit for $63 million.
• Launched a restructuring plan in 2024 to simplify organizational structure and consolidate facilities for better efficiency.
• Authorized a new share repurchase program in December 2025 to buy back up to $250 million of common stock through 2028.

Global Reach and Technology

Azenta maintains a large global footprint with significant operations in the United States, China, and Europe. The company uses precision automation and cryogenic technology to manage sensitive medical samples across the entire research life cycle.

The Scorecard

• Revenue reached $148.6 million in Q1 2026, up 0.8% from $147.4 million in Q1 2025.
• Operating loss reached $4.9 million in Q1 2026, worsening 33.5% from a $3.7 million loss in Q1 2025.
• Net loss reached $15.4 million in Q1 2026, worsening 40.4% from $11 million in the previous year.
• Free cash flow was $14.7 million in Q1 2026, down 33.5% from $22 million in Q1 2025.
• Cash and cash equivalents of continuing operations grew to $336.6 million as of December 31, 2025.

Bottom Line

Azenta is transitioning into a specialized life sciences provider by divesting non-core assets like its temperature-controlled transportation business. This focus on automated storage and genomic services aligns with the growing demand for high-tech drug development tools.